Arcus Biosciences and partner Gilead disclosed a Phase 3 futility finding for domvanalimab, an anti‑TIGIT antibody, in an upper‑gastrointestinal cancer study; an independent data monitoring committee recommended stopping the trial for lack of efficacy. The companies announced cancellation or suspension of related domvanalimab trials and said Arcus will realign R&D priorities around other assets and indications. The setback joins a string of recent clinical disappointments for TIGIT programs and has prompted both firms to reassess investment in the target. Investors and R&D teams are recalibrating timelines for combination immunotherapy strategies that had hinged on TIGIT blockade.